{"id":26257,"date":"2023-12-15T22:32:34","date_gmt":"2023-12-15T17:02:34","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=26257"},"modified":"2024-09-17T16:57:53","modified_gmt":"2024-09-17T11:27:53","slug":"golcadomide-and-rituximab-combo-in-dlbcl-patients","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/golcadomide-and-rituximab-combo-in-dlbcl-patients","title":{"rendered":"Golcadomide and Rituximab Combo Unveils Promising Efficacy in Heavily Pretreated Relapsed\/Refractory DLBCL"},"content":{"rendered":"\n
Date of Abstract presentation<\/td>11th December 2023<\/td><\/tr>
Indications<\/td>Diffuse large B-cell lymphoma (DLBCL)<\/td><\/tr>
Abstract Number<\/td>4496<\/td><\/tr>
Abstract type<\/td>Poster<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Diffuse large B-cell lymphoma (DLBCL) stands as a swiftly progressing and aggressive ailment, representing the predominant type of non-Hodgkin lymphoma (NHL) and encompassing one-third of all diagnosed cases. Over two-thirds of DLBCL patients face either non-response or relapse after second-line treatment. Those experiencing relapse or inadequate response to initial interventions confront a scarcity of conventional treatment choices that offer sustained remission, leading to a median life expectancy of approximately six months. This underscores a pressing demand for innovative therapies to address this critical unmet medical need. As per the results presented at the ASH 2023 conference, there were 26 patients evaluated for efficacy, and the overall response rate (ORR) reported was 42%, <\/strong>with 19% of patients achieving a complete response (CR). Moreover, the median duration of response was 7.5 months. Apart from that, the ORR and CR rate was greater for patients in the 0.4 mg arm compared to the 0.2 arm.<\/p>\n\n\n\n

In terms of safety assessment, neutropenia emerged as the predominant treatment-emergent adverse event (TEAE) of any grade, affecting 50% of the participants. Among the reported serious adverse events, pneumonia, and pyrexia were the only occurrences observed in more than one patient, each reported in two cases. Throughout the study, four deaths occurred during treatment, with one related to the study treatment.<\/strong><\/p>\n\n\n\n

KOL Insights<\/strong><\/h2>\n\n\n\n
\n

\u201cGolcadomide is a novel, oral CELMoD agent representing one of several compelling assets generated from our differentiated targeted protein degradation research platform. \u201cIn the studies being presented at ASH 2023, golcadomide has shown potential warranting further evaluation in patients with first-line and previously treated large B-cell lymphomas. We are encouraged by the growing body of evidence for this purposefully designed lymphoma agent as we continue toward a registrational program.\u201d \u2013Expert Opinion.<\/strong><\/p>\n<\/blockquote>\n\n\n\n

Conclusion<\/strong><\/h2>\n\n\n\n

The combination of oral golcadomide therapy with rituximab demonstrated encouraging effectiveness in patients with R\/R DLBCL who had undergone extensive prior treatments.<\/p>\n\n\n\n

Refer to the Related Reports for More In-depth Insights –<\/strong><\/p>\n\n\n\n

\n
\n

Multiple Myeloma Market<\/a><\/strong><\/p>\n\n\n\n

Diffuse Large B-cell Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Marginal Zone Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Acute Lymphocytic Leukemia (ALL) Market<\/a><\/strong><\/p>\n\n\n\n

Chronic Lymphocytic Leukemia Market<\/a><\/strong><\/p>\n<\/div>\n\n\n\n

\n

Mantle Cell Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Hodgkin’s lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Myelofibrosis Market<\/a><\/strong><\/p>\n\n\n\n

Myelodysplastic Syndrome Market<\/a><\/strong><\/p>\n\n\n\n

Follicular Lymphoma Market<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Date of Abstract presentation 11th December 2023 Indications Diffuse large B-cell lymphoma (DLBCL) Abstract Number 4496 Abstract type Poster Diffuse large B-cell lymphoma (DLBCL) stands as a swiftly progressing and aggressive ailment, representing the predominant type of non-Hodgkin lymphoma (NHL) and encompassing one-third of all diagnosed cases. Over two-thirds of DLBCL patients face either non-response […]<\/p>\n","protected":false},"author":6,"featured_media":26296,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[20413,20004,21525,21534,21533,20617,137,841,927,19118],"industry":[17225],"therapeutic_areas":[17233,17228],"class_list":["post-26257","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-abstracts","tag-american-society-of-hematology","tag-ash-2023","tag-ash-abstracts","tag-ash-annual-meeting-abstracts","tag-b-cell-lymphoma","tag-cancer","tag-cancer-research","tag-cancer-treatment","tag-large-b-cell-lymphoma","industry-pharmaceutical","therapeutic_areas-hematological-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nGolcadomide and Rituximab Combo in Patient with DLBCL<\/title>\n<meta name=\"description\" content=\"The combination of oral golcadomide therapy with rituximab demonstrated encouraging effectiveness in patients with R\/R DLBCL.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/golcadomide-and-rituximab-combo-in-dlbcl-patients\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Golcadomide and Rituximab Combo in Patient with DLBCL\" \/>\n<meta property=\"og:description\" content=\"The combination of oral golcadomide therapy with rituximab demonstrated encouraging effectiveness in patients with R\/R DLBCL.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/golcadomide-and-rituximab-combo-in-dlbcl-patients\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-15T17:02:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-17T11:27:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/15223040\/golcadomide-and-rituximab-combo-in-patients-with-dlbcl.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Golcadomide and Rituximab Combo in Patient with DLBCL","description":"The combination of oral golcadomide therapy with rituximab demonstrated encouraging effectiveness in patients with R\/R DLBCL.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/golcadomide-and-rituximab-combo-in-dlbcl-patients","og_locale":"en_US","og_type":"article","og_title":"Golcadomide and Rituximab Combo in Patient with DLBCL","og_description":"The combination of oral golcadomide therapy with rituximab demonstrated encouraging effectiveness in patients with R\/R DLBCL.","og_url":"https:\/\/www.delveinsight.com\/blog\/golcadomide-and-rituximab-combo-in-dlbcl-patients","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-12-15T17:02:34+00:00","article_modified_time":"2024-09-17T11:27:53+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/15223040\/golcadomide-and-rituximab-combo-in-patients-with-dlbcl.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/golcadomide-and-rituximab-combo-in-dlbcl-patients","url":"https:\/\/www.delveinsight.com\/blog\/golcadomide-and-rituximab-combo-in-dlbcl-patients","name":"Golcadomide and Rituximab Combo in Patient with DLBCL","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/golcadomide-and-rituximab-combo-in-dlbcl-patients#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/golcadomide-and-rituximab-combo-in-dlbcl-patients#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/15223040\/golcadomide-and-rituximab-combo-in-patients-with-dlbcl.png","datePublished":"2023-12-15T17:02:34+00:00","dateModified":"2024-09-17T11:27:53+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"The combination of oral golcadomide therapy with rituximab demonstrated encouraging effectiveness in patients with R\/R DLBCL.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/golcadomide-and-rituximab-combo-in-dlbcl-patients"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/golcadomide-and-rituximab-combo-in-dlbcl-patients#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/15223040\/golcadomide-and-rituximab-combo-in-patients-with-dlbcl.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/15223040\/golcadomide-and-rituximab-combo-in-patients-with-dlbcl.png","width":1200,"height":800,"caption":"Golcadomide-Rituximab Combo in DLBCL Patient"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/15223040\/golcadomide-and-rituximab-combo-in-patients-with-dlbcl-300x200.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">American Society of Hematology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH 2023<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH Annual Meeting Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">B-cell Lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Large B-cell Lymphoma<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Abstracts<\/span>","<span class=\"advgb-post-tax-term\">American Society of Hematology<\/span>","<span class=\"advgb-post-tax-term\">ASH 2023<\/span>","<span class=\"advgb-post-tax-term\">ASH Abstracts<\/span>","<span class=\"advgb-post-tax-term\">ASH Annual Meeting Abstracts<\/span>","<span class=\"advgb-post-tax-term\">B-cell Lymphoma<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">Cancer research<\/span>","<span class=\"advgb-post-tax-term\">Cancer Treatment<\/span>","<span class=\"advgb-post-tax-term\">Large B-cell Lymphoma<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Dec 15, 2023","modified":"Updated on Sep 17, 2024"},"absolute_dates_time":{"created":"Posted on Dec 15, 2023 10:32 pm","modified":"Updated on Sep 17, 2024 4:57 pm"},"featured_img_caption":"Golcadomide-Rituximab Combo in DLBCL Patient ","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26257","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=26257"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26257\/revisions"}],"predecessor-version":[{"id":28008,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26257\/revisions\/28008"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/26296"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=26257"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=26257"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=26257"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=26257"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=26257"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}